Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (47)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Daly, J. S.
Right arrow Articles by Moellering, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daly, J. S.
Right arrow Articles by Moellering, R. C., Jr
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1988) 21, 721-730
© 1988 The British Society for Antimicrobial Chemotherapy

research-article

Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds

Jennifer S. Dalya,b,*, George M. Eliopoulosa,b,, Edina Reisznera and Robert C. Moellering, Jra,b

aDepartment of Medicine, New England Deaconess Hospital bHarvard Medical School Boston, MA 02215, USA

Received 30 October 1987; accepted 2 February 1988

Correspondence address: Dr George M. Eliopoulos, Department of Medicine, New England Deaconess Hospital, 110 Francis Street, Boston, MA 02215, USA

The in-vitro activities of DuP 721 and DuP 105, new oxazolidinone antibacterials, were compared with those of cefazolin, cephalexin, ciprofloxacin, clindamycin, oxacillin, penicillin, and vancomycin against Gram-positive cocci. DuP 721 was approximately four-fold more active than DuP 105 with an MIC of 2·0 mg/l for 90% of the Staphylococcus aureus, ß-haemolytic streptococcus and Streptococcus faecalis strains tested, and an MIC of 4·0 mg/l for 90% of the Str. faecium, penicillin-resistant Str. pneumoniae and viridans streptococcus strains tested. DuP 105 was most active against strains of Staph. epidermidis with an MIC of 4·0 mg/l for 90% of the strains tested. There was no cross resistance between these and the other antibacterial agents that were tested. Both oxazolidinones had bacteriostatic activity in broth against susceptible organisms. Both DuP 721 and DuP 105 inhibited ribosomal protein synthesis in a cell-free system. These synthetic, orally absorbable compounds represent a new series of antibacterial agents unrelated by chemical structure to any other currently available antimicrobial agents.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
G. Grunder, Y. Zysset-Aschmann, F. Vollenweider, T. Maier, S. Krahenbuhl, and J. Drewe
Lack of Pharmacokinetic Interaction between Linezolid and Antacid in Healthy Volunteers
Antimicrob. Agents Chemother., January 1, 2006; 50(1): 68 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. J. Yoon, Y. W. Jo, S. H. Choi, T. H. Lee, J. K. Rhee, M. Yoo, M. J. Shim, and E. C. Choi
In Vitro and In Vivo Activities of DA-7867, a New Oxazolidinone, against Aerobic Gram-Positive Bacteria
Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2498 - 2500.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Grohs, M.-D. Kitzis, and L. Gutmann
In Vitro Bactericidal Activities of Linezolid in Combination with Vancomycin, Gentamicin, Ciprofloxacin, Fusidic Acid, and Rifampin against Staphylococcus aureus
Antimicrob. Agents Chemother., January 1, 2003; 47(1): 418 - 420.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. C. Fluit, F.-J. Schmitz, and D. Milatovic
The presence of ermB in Streptococcus pneumoniae has no influence on AZD2563 MIC values
J. Antimicrob. Chemother., January 1, 2003; 51(1): 184 - 185.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Prystowsky, F. Siddiqui, J. Chosay, D. L. Shinabarger, J. Millichap, L. R. Peterson, and G. A. Noskin
Resistance to Linezolid: Characterization of Mutations in rRNA and Comparison of Their Occurrences in Vancomycin-Resistant Enterococci
Antimicrob. Agents Chemother., July 1, 2001; 45(7): 2154 - 2156.
[Abstract] [Full Text] [PDF]

Home page
 J. Bacteriol.Home page
L. Xiong, P. Kloss, S. Douthwaite, N. M. Andersen, S. Swaney, D. L. Shinabarger, and A. S. Mankin
Oxazolidinone Resistance Mutations in 23S rRNA of Escherichia coli Reveal the Central Region of Domain V as the Primary Site of Drug Action
J. Bacteriol., October 1, 2000; 182(19): 5325 - 5331.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
M. Fines and R. Leclercq
Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors
J. Antimicrob. Chemother., June 1, 2000; 45(6): 797 - 802.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. A. Noskin, F. Siddiqui, V. Stosor, D. Hacek, and L. R. Peterson
In Vitro Activities of Linezolid against Important Gram-Positive Bacterial Pathogens Including Vancomycin-Resistant Enterococci
Antimicrob. Agents Chemother., August 1, 1999; 43(8): 2059 - 2062.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
M. E. Jones, M. R. Visser, M. Klootwijk, P. Heisig, J. Verhoef, and F.-J. Schmitz
Comparative Activities of Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, Ofloxacin, Sparfloxacin, and Trovafloxacin and Nonquinolones Linozelid, Quinupristin-Dalfopristin, Gentamicin, and Vancomycin against Clinical Isolates of Ciprofloxacin-Resistant and -Susceptible Staphylococcus aureus Strains
Antimicrob. Agents Chemother., February 1, 1999; 43(2): 421 - 423.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
M. J. Rybak, D. M. Cappelletty, T. Moldovan, J. R. Aeschlimann, and G. W. Kaatz
Comparative In Vitro Activities and Postantibiotic Effects of the Oxazolidinone Compounds Eperezolid (PNU-100592) and Linezolid (PNU-100766) versus Vancomycin against Staphylococcus aureus, Coagulase-Negative Staphylococci, Enterococcus faecalis, and Enterococcus faecium
Antimicrob. Agents Chemother., March 1, 1998; 42(3): 721 - 724.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.